patents.google.com

CA2039599A1 - Solid support having antibodies immobilized thereon - Google Patents

  • ️Tue Nov 19 1991

CA2039599A1 - Solid support having antibodies immobilized thereon - Google Patents

Solid support having antibodies immobilized thereon

Info

Publication number
CA2039599A1
CA2039599A1 CA 2039599 CA2039599A CA2039599A1 CA 2039599 A1 CA2039599 A1 CA 2039599A1 CA 2039599 CA2039599 CA 2039599 CA 2039599 A CA2039599 A CA 2039599A CA 2039599 A1 CA2039599 A1 CA 2039599A1 Authority
CA
Canada
Prior art keywords
antibody
solid support
specific
nonspecific
immobilized
Prior art date
1990-05-18
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2039599
Other languages
French (fr)
Inventor
Izak Bahar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PB Diagnostic Sytems Inc
Original Assignee
PB Diagnostic Sytems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1990-05-18
Filing date
1991-04-02
Publication date
1991-11-19
1991-04-02 Application filed by PB Diagnostic Sytems Inc filed Critical PB Diagnostic Sytems Inc
1991-11-19 Publication of CA2039599A1 publication Critical patent/CA2039599A1/en
Status Abandoned legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366Apparatus specially adapted for solid-phase testing
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/551Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being inorganic
    • G01N33/552Glass or silica
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • G01N33/6857Antibody fragments

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SOLID SUPPORT HAVING ANTIBODIES IMMOBILIZED THEREON

ABSTRACT OF THE DISCLOSURE
There is disclosed a solid support having antibodies immobilized thereon. The specific antibodies of interest are immobilized on the solid support as part of a complex which includes a nonspecific antibody and an antibody directed against the Fc fragments of the specific and nonspecific antibodies. In a preferred embodiment the solid support is used in solid phase competitive immunoassays and provides improved signal levels and desirable steeper standard curve slopes in the desired assay sensitivity range.

Description

~3~

SOLID SUPPORT HAVING ANTIBODIES iMMC)BlLlZED Tl IEREON

BACKGROUND OF THE INVENTION
This invention relates to solid suppor~s having antibodies immobilized thereon and, more particularly, to such solid supports which are useful in solid phase immunoassays.
Various types of assay elements are known for use in immunoassays to analyze for analytes present in biological fluids. in one type which is commonly referred to as a solid phase immunoassay, one member of the antigen-antibody interac~ion pair, e.g., the antibody, is bound to a solid carrier such as particulate materials, fibrous materials and the like. In these assays the soiid support becomes the site at which the interaction between ~he bound material and a binding partner takes place.
Any of the known immunometric assays, e.g., sandwich or competitive assays, can be carried out in the solid phase format.
Such assays are well known to those skilled in the art. Briefly, for example, in the competitive assay a sample fluid containing an analyte 5 ~ ~

of interest, e.g., an antigen, is applied to a solid support having bound thereto a binding partner of the analyte, e.g., an antibody. The amount of antibody bound to the support is that necessary to allow the requisite competition between the sample analyte and the labeled 5 species. Subsequently, after a period of incubation, a labeled analyte or a labeled analo~ue thereof is added to the solid support and after another incubation period and a wash step to remove any unbound labeled material, the bound labeled material is detected to provide a signal which is a function of the amount of analyte in the patient 10 sample fluid. The signal is inversely proportional to the amount of analyte in the sample.
The antibodies which are immobilized on the solid carrier can be bound thereto by various means including covalent binding, immunoprecipitation and the like~ The immunoprecipitation technique 15 can be carried out more conveniently as compared to the chemical reaction(s) required for covalent binding. I lowever, in some assays such as the competitive immunoassay described previously, only a relatively limited amount of antibodies may be bound to the carrier because of various factors such as the assay concentration range, etc.
20 If the binding technique employed is not efficient enough a low signal level may be obtained with a given amount of antibodies. Of course, the signal can be improved by adding more antibodies to the solid carrier but this alternative is not satisfactory if it results in the assay range being shifted outside of the range required for the analyte of 25 interest.
Accordingly, it would be desirable to have new solid supports having antibodies immobilized thereon. It would also be 2~3~3~9l~

desirable to have such solid supports which could be used in competitive solid phase immunoassays to provide improved signal levels while at the same time exhibiting low nonspecific binding.
SUMMARY ~F THE II~IVENTION
These and other objects and advantages are accornplished in accordance with the invention by providing a solid support having immobilized thereon a compl~x of a specific antibody of interest, a nonspecific antibody and an antibody directed against the Fc fragments of the specific and nonspecific antibodies. For example, consider a mouse monoclonal anti-digoxin antibody as the specific antibody of interest vvhich is to be immobilized on a solid support for use in an immunoassay for digoxin. According to the invention the mouse monoclonal anti-digoxin antibodies are included in a complex together with an anti-mouse antibody which is raised against the Fc fragments of mouse antibodies and a mouse IgG antibody which is nonspecific.
The complex is immobilized on the solid support by passive adsorption.
The solid supports o-f the invention are prepared by initially mixing the antibody of interest, e.g., the anti-digoxin antibody, with the nonspecific antibody in a coating solution, typically a buffer solution, and then adding the specific antibody raised against the Fc fragments of the specific and nonspecific antibodies. The mixture is incubated under time and temperature conditions which allow the complex to form. The coating solution is applied ~o ~he soiid support and the latter is dried. The antibody complex is immobilized to the solid support through passive adsorption.
The solid supports of the invention have been found to be particularly advantageous when used in competitive solid phase immunoassays for the analysis of anal'ytes in a sample fluid. Higher signal levels can be obtained while at 1:he same tirne maintaining th sensitivity of the assay in the desired assay ran~e.
BRIEF DESCRIPTIQN QF 1HE_DRAWli~
For a better understandin~ of the invention as well as other objects and further features thereof, reFerence is made to the following detailed description of the preferred embodiments thereof taken in conjunction with the accompanyin~ drawing wherein the Figure is a simplified, isometric view of a pre~erred assay element in accordance with the invention.
DESCRIPTION OF THE PREFERRED EMBODIMENT
The solid supports of the invention may comprise any suitable solid carrier such as, for example, particulate materials, porous members possessing an intercommunicating network of openings throughout such that a fluid deposited on the member will propagate through the member, and the like. Suitable porous members include porous membranes, fibrous mesh materials and the lika and may be of any sui~able material such as glass, polymeric materials, paper, etc. In a preferred embodiment the solid carrier is a thin fibrous mesh member which will permit fluid deposited thereon to propagate throughout because of capillary action. The member may be any suitable fibrous material; a preferred material is a nonwoven glass fiber mesh, the fibers being very thin such as on the order of about 1 micrometer (,um).
Any monoclonal antibodie~ of interest may be immobilized on the solid carrier such as, for exampla, antibodies to: haptens such as digoxin, triiodothyronine (T3) and the iike; pro~eins such as myoglobin; horrnones; etc. The nonspecific antibody may be any to which the antibody directed against the Fc frayments of the specific and nonspecific antibodies will bind. I'referably the nonspecific antibody is of the same species as the specific antibody, i.e., they are both raised in the same type of host animal, e.g., rnice. The antibody 5 which is raised ayainst the Fc fragrnents of the specific and nonspecific antibodies can be raised in any host animal.
The coatin0 solution which is used to apply the antibody complex to the solid support is prepared by initially combining the specific antibody of interest and the nonspecific antibody in an 10 appropriate solution, preferably a buffer solution. The solution may contain other additives such as, for example, proteins which are useful for reducing nonspecific binding, stabilizers such as sugars, surfactants which improve the wettability of the solid support and preservatives for preventing anti-microbial action. Subse~uently, the antibody 15 directed against the Fc fragmen~s of the specific and nonspecific antibodies is added. The solution is then incubated under time and temperature conditions which are required to allow the complex formation to occur. These conditions will vary depending upon ~he specific materials, the amounts involved, etc~ In a preferred 20 embodiment the coating solution is incubated at 37C for about one hour.
The soiution is then deposited on the solid support and allowed to become immobilized thereon through passive adsorption.
The solid support is dried to provide a member which is useful in solid 2~ phase immunoassays.
In a preferred embodiment the solid supports of the invention are utilized in the known competitive solid phase 2 ~

immunometric assays for an analyte ol interest. Such assays are well known to those skilled in the art and extensive discussion thereof is not required here. To further describe the advantages of the solid supports of the invention their use in a preferred fibrous solid phase competitive immunoassay will be described. Refefring now to the Figure there is seen an assay element 10 which includes a plurality of chambers in a housing 12 wherein a first chamber 14 serves as a front reservoir for the storage of a fluid reagent to be utili~ed in the assay, a second of the chambers serves as a back reservoir 16 for the storage of another fluid reagent for the assay, a third chamber 18 serves a mixing well for mixing reagents and fourth chamber 20 is adapted to dispense a fluid to one end of a porous solid support 22. There is also shown a chamber 24 within the housing 12 wherein there is arranged an absorbing material for absorbing fluid removed from solid support 22 such as by a wash fluid as the latter propagates through the fibrous solid support. A frangible as puncturable foil (not shown) is disposed over the front and back reservoirs, 14 and 16, respectively, for containing the fiuid reagents within these reservoirs thus providing a self contained assay element.
The solid support 22 in this preferred embodiment comprises a thin fibrous mesh pad to which there has been immobilized an antibody of interest in accordance with the invention. A preferred solid support is a nonwoven glass fiber mesh having very thin Fibers such as on the order of about 1 micrometer (,um). This preferred solid support is from about 0.30 mm to about 0.60 mm in thickness, preferably about 0.40 mm.

The solid support 22 extends from the dispensing chamber 20 to the chamber 2~ which holds the absorbing material.
The fluid absorbing material 26, which may be any suitable material, is located within chamber 24 and forms ia part of the chamber 24 for 5 taking up fluid expelled frorn the solid support and the guide area (not shown) in which the support is arranged. The absorbing material 26 is located contiguous the solid support 22 and in a preferred embodiment, as illustrated, is formed conveniently as an extension of the solid support material folded back and forth on itself.
The housing 12 also includes a chamber 28 which is positioned immediately above the area of the solid support where the immunometric interactions take place. It wili be apparent to those skilled in the art that the immobilized antibody comple~ bound to the solid support need only be present on that part of the support where 15 the immunometric interactions will take place. The housin~ 12 also preferably includes a transparent window (not shown) or an opening in the housing, positioned immediately below the bottom surface of the solid support 22 to provide access for the readout illumination used to measure the detectable change effected in the support as a result of 20 the assay method.
In the assay method a volume of sample fluid, typically 30-45 ~l is deposited on the solid support 22 through chamber 28.
The sample fluid is allowed to incubate for a suitable period at the appropriate temperature to allow the sample antigen to interact with 25 the immobilized antibodies in the reaction site on the solid support.
Subsequently, a conjugate of an enzyme-labeled antigen ~the same as the sample antigen) or an analogue thereof is withdrawn fro 2 ~ 3 chamber 14 and deposited on the soiid support through chamber 28.
The conjugate will bind to any specific antibodies on the solid support which are not bound to the sample antigen. The assay elemen~ 10 is again allowed to incubate.
Since the enzyrr,e label must be detected indirectly, a substrate solution, typically 50-100 ~1 is applied to the porous solid support 22 through chamber 20. The substrate solution is utilized both as a wash fluid to remove From the solid support any unbound sample anti~en or conjugate and to render the enzyme label detectable.
The substrate solution is caused to enter an end portion of the solid support and as the solu~ion propagates through the solid support 22 it forces any unbound sample antigen and enzyrne conjugate together with the fluid out of the solid support and into the absc)rber chamber 24 where it is taken up by the absorber material 26. The si0nal provided by the fluorescent species liberated by the reaction of the enzyme with the substrate material is read out by means of suitable optical apparatus.
It has been found that such competitive assays carried out with the solid supports of the invention provide higher signal levels and desirably steeper standard curve slopes in the assay range.
Although the preferred competitive solid phase assay has been described with respect to a sequential format it should be recognized that it can also be carried out in the simultaneous mode.
The invention will now be described further in detail with respect to specific preferred embodiments by way of examples it bein~
understood that these are intended to be illustrative only and the ~ ~3 Q~ $ ~

g invention is not limited to the materials, conditions, process parameters, etc. which are recited therein.
EXAMPL.E I
An antibody solution was prepared containing 0.1 ~/ml of anti-digoxin antibodies and 10 ,ug/ml of mouse IgG antibodies in a pH 7.2 phosphate buffered saline solution whi~h also contained other proteins, stabilizers, surfactants and anti-microbial a~ents. The solution was filtered through a 0.2,um filter and then 2 ml of a solution of Goat Anti-Mouse IgG, Fc Fragment Specific (Jackson ImmunoResearch) was diluted 1:100 with the antibody solution to form a coating solution.
The coating solution was incubated for one hour at 37C
and about 35 IJI added to an approximately 7 x 8 mm area of a Whatman GF/F fibrous glass filter material. The filter material was dried for about 10 rninutes at 75C and incorpora~ed into an assay element as described previously.
The assay elements were then used to carry out the competitive immunometric assay method previously described with sample fluids containing known digoxin concentrations. The assays were carried out on an automated laboratory instrument. The enzyme label used in the conjugate was methyl umbelliferyl phosphate and the readout signal was obtained by directed 360 nm radiation upon the bottom surface of the solid support and measuring the reflected 450 nm radiation.
The signals obtain-sd are shown in Table 1. The assays were read kinetically and the si~nals obtained are the slopes of the ~J ~

kinetic measurements. Each value shown in Table I is the avera~e of three replicates.
Table I
Diqoxin (nq/mll Signal 0.00 2372 0.50 191 1 1.00 1 275 2.û0 672 4,00 25 1 It can be seen that the assay method of the invention provided high signal levels and a desirable steep standard curve slope in the assay range (about 0.5 - 4.0 ng/ml).

A coating solution was prepared which was the same as 15 that described in Example I except that it contained O.Q625 l~g/ml of a monoclonal antibody to T3 instead of -the anti-digoxin antibodies.
Assay elements were prepared as described in Example I and used to carry out the competitive solid phase assay method previously described. The results obtained are shown in Table ll.
Table ll T3 (ngLml) ~L~
0.00 5973 0.50 5279 1.00 44g7 2.00 3072 4,00 1 98~
~,oo 1 220 ~3~

Again the assay method of the invention provided high signal levels and a desirable s~eep standard curve slope in the assay range (about 0.50 - 8.0Q ng/ml).
Although the invention has been describ0d in detail with 5 respect to various preferred embodiments, those skilled in the art will recognize that variations and modifications may be made therein which are within the spirit of the invention and the scope of the appended claims .

Claims (16)

1. A solid support having an antibody of interest immobilized thereon comprising a solid support to which there is attached a complex of: (1) a specific monoclonal antibody of interest;
(2) a nonspecific antibody; and (3) an antibody directed against the Fc fragments of said specific and nonspecific antibodies.

2. The solid support as defined in claim 1 wherein said solid support is a fibrous glass material.

3. The solid support as defined in claim 2 wherein said specific monoclonal antibody is a mouse anti-digoxin antibody or a mouse anti-triiodothyronine (T3) antibody, said nonspecific antibody is a mouse IgG antibody and said antibody directed against the Fc fragments of said specific and nonspecific antibodies is a goat anti-mouse antibody.

4. The solid support as defined in claim 1 wherein the specific antibody and the nonspecific antibody are of the same species.

5. A method for preparing a solid support having an antibody of interest immobilized thereon comprising (a) adding to a solution containing a specific monoclonal antibody of interest and a nonspecific antibody, an antibody directed against the Fc fragments of said specific and nonspecific antibodies;
(b) incubating said solution at a temperature and for a period of time sufficient to allow said antibodies to form a complex;
(c) applying said solution to a solid support and (d) drying said solid support whereby said antibody complex is immobilized on the solid support.

6. The method as defined in claim 5 wherein said solid support is a fibrous glass material.

7. The method as defined in claim claim 5 wherein step (b) is carried out at about 37°C for about one hour.

8. The method as defined in claim 5 wherein said specific and nonspecific antibodies are of the same species.

9. The method as defined in claim 8 wherein said specific antibody is a mouse monoclonal antibody and said nonspecific antibody is a mouse IgG antibody.

10. The method as defined in claim 9 wherein said specific antibody is a mouse anti-digoxin antibody or a mouse anti-triiodothyronine (T3) antibody.

11. A competitive solid phase immunoassay method comprising (a) contacting a solid support as defined in claim 1 with (i) a sample fluid containing an analyte which is the binding partner of the specific monoclonal antibody immobilized on said solid support and (ii) a conjugate comprising a label bound to said analyte or an analogue thereof;
(b) separating the solid and fluid phases; and (c) detecting the amount of the label present in either the solid or fluid phase.

12. The method as defined in claim 11 wherein said label is an enzyme and step (b) is carried out by applying a substrate solution to said solid support.

13. The method as defined in claim 12 wherein the reaction of said substrate and said enzyme provides a fluorescent species.

14. The method as defined in claim 11 wherein step (a) is carried out by first applying said sample fluid to said solid support and then applying a solution of said conjugate to the solid support.

15. The method as defined in claim 11 wherein said specific monoclonal antibody immobilized on said solid support is a monoclonal anti-digoxin antibody or a monoclonal anti-triiodothyronine (T3) antibody.

16. The method as defined in claim 14 wherein said specific monoclonal antibody immobilized on said solid support is a monoclonal anti-digoxin antibody or a monoclonal anti-triiodothyronine (T3) antibody.

CA 2039599 1990-05-18 1991-04-02 Solid support having antibodies immobilized thereon Abandoned CA2039599A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52658090A 1990-05-18 1990-05-18
US526,580 1990-05-18

Publications (1)

Publication Number Publication Date
CA2039599A1 true CA2039599A1 (en) 1991-11-19

Family

ID=24097912

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2039599 Abandoned CA2039599A1 (en) 1990-05-18 1991-04-02 Solid support having antibodies immobilized thereon

Country Status (4)

Country Link
EP (1) EP0483309A1 (en)
JP (1) JPH05500116A (en)
CA (1) CA2039599A1 (en)
WO (1) WO1991018291A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06505803A (en) * 1992-01-06 1994-06-30 デイド、インターナショナル、インコーポレイテッド Multitest immunochemical reagents and methods for their use
CA2093494A1 (en) * 1992-04-17 1993-10-18 Keisuke Iwata Method for the elimination of non-specific reactions in immuno-assays
US5399500A (en) * 1992-06-26 1995-03-21 Becton Dickinson And Company Two step process for coating of antibodies to a solid phase
DE19505204A1 (en) * 1995-02-16 1996-08-22 Behringwerke Ag Modification of the reactivity of agglutination reagents by co-coating with substances not directed against the analyte
US20050069962A1 (en) 2001-10-12 2005-03-31 Archer Robert M Antibody complexes and methods for immunolabeling
JP7222550B2 (en) * 2017-03-13 2023-02-15 イントリンシック ライフサイエンシズ リミテッド ライアビリティ カンパニー Human erythroferon antibody and use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3799742A (en) * 1971-12-20 1974-03-26 C Coleman Miniaturized integrated analytical test container
US4803167A (en) * 1982-03-30 1989-02-07 The General Hospital Corporation Monoclonal antidigoxtin antibodies
US4606855A (en) * 1982-07-26 1986-08-19 Mex Research Associates C/O Leon Reimer Monoclonal antibody to digoxin
FR2556840B1 (en) * 1983-12-16 1987-12-24 Immunotech Sa PROCESS FOR THE IN VITRO ASSAY OF IMMUNOGLOBULINS SPECIFIC TO ONE OR MORE ALLERGENS AND REAGENTS AND MEANS FOR CARRYING OUT THIS METHOD
US4918025A (en) * 1987-03-03 1990-04-17 Pb Diagnostic Systems, Inc. Self contained immunoassay element
DE3718140A1 (en) * 1987-05-29 1988-12-08 Boehringer Mannheim Gmbh HETEROGENIC IMMUNOASSAY
JPS6488367A (en) * 1987-09-30 1989-04-03 Japan Chem Res Immobilized antibody

Also Published As

Publication number Publication date
WO1991018291A1 (en) 1991-11-28
EP0483309A1 (en) 1992-05-06
JPH05500116A (en) 1993-01-14

Similar Documents

Publication Publication Date Title
CA1236011A (en) 1988-05-03 Assay method for whole blood samples
JP2590059B2 (en) 1997-03-12 Chromatography apparatus and measurement method using the same
AU689174B2 (en) 1998-03-26 Sensor device for sandwich assay
US5160486A (en) 1992-11-03 Test carrier utilizing reaction of two bioaffine binding partners
US5079142A (en) 1992-01-07 Orthogonal flow immunoassays and devices
US4959307A (en) 1990-09-25 Immunoseparating strip
AU714613B2 (en) 2000-01-06 Method for amplification of the response signal in a sandwich immunoassay
US4777128A (en) 1988-10-11 Fluorescence immunoassay involving energy transfer between two fluorophores
EP1917529B1 (en) 2010-06-30 Analyte assaying by means of immunochromatography with lateral migration
US20040018576A1 (en) 2004-01-29 Bence Jones protein testing cassette
JPH0627738B2 (en) 1994-04-13 Specific binding assay device and method
US6689317B1 (en) 2004-02-10 Immunoassay apparatus for diagnosis
JPH08508569A (en) 1996-09-10 Opposite member chromatography assay device
IE903118A1 (en) 1991-03-27 Test device including flow control means
US5085988A (en) 1992-02-04 Immunoseparating strip
CA1274174A (en) 1990-09-18 Analytical device and method for using same
WO1982000363A1 (en) 1982-02-04 Immunosubstrate and immunoadsorptive surface coating for solid-phase immunosubstrate
US5260193A (en) 1993-11-09 Immunoseparating strip
CA2009111A1 (en) 1990-08-02 Method and device for quantitative chromatography
CA2039599A1 (en) 1991-11-19 Solid support having antibodies immobilized thereon
CA2008100A1 (en) 1990-07-20 Method for the determination of immunologically detectable substance
JPS63210664A (en) 1988-09-01 Dry test piece for device using oxygen demand detection system and detecting method of analytic component in fluid to be inspected
JPS63210772A (en) 1988-09-01 Dry test piece and detecting method of analytic component in fluid to be inspected using said test piece
EP0253581B1 (en) 1991-10-16 Analytical element having water-soluble polymers and determinations using same
AU647428B2 (en) 1994-03-24 Immunoassay for antibodies to infectious disease agents

Legal Events

Date Code Title Description
1993-10-04 FZDE Dead